A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
Completed · Phase 3 · NCT05681715
Conditions: Generalized Myasthenia Gravis
At a glance
- Research payments reported, 2025
- $21,117
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 62
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- Rozanolixizumab (drug)
- Dates
- Started 2023-04-17; completion 2024-04-23
- Results posted
- Yes
The purpose of this study is to evaluate the ability of study participants with generalized Myasthenia Gravis (gMG) to successfully self-administer rozanolixizumab after training in the self-administration technique using the syringe driver and manual push methods.
From ClinicalTrials.gov, last updated 2025-11-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $21,117 in research payments for this study in 2025 (1 payments).
Products named: Rystiggo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.